Hepatic Artery Atherosclerosis Is a Risk Factor for Biliary Strictures After Liver Transplantation [0.03%]
肝动脉粥样硬化是肝脏移植后胆道狭窄的风险因素
Paloma E Alañón-Martínez,Marina Orti-Cuerva,Ana Luque-López et al.
Paloma E Alañón-Martínez et al.
Background and aims: The aging of liver donors and transplant candidates, along with the growing prevalence of metabolic comorbidities, may lead to hepatic artery atherosclerosis. Since the biliary epithelium relies on ar...
Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics? [0.03%]
胆汁淤积中回肠胆汁酸转运抑制剂：不仅仅用于儿科的潜力？
Mahesh Krishna,James Lorenzen Boyer
Mahesh Krishna
Ileal bile acid transporter inhibitors (IBATi) are a new, attractive therapeutic mechanism to alter the enterohepatic circulation through depletion of the bile acid pool by blocking bile acid reuptake in the ileum leading to improvements in...
Response to 'Reassessing the Clinical Interpretation of Atezolizumab Plus Bevacizumab in Child-Pugh B Hepatocellular Carcinoma' [0.03%]
“重新评估贝伐珠单抗联合阿特朱单抗治疗巴克拉夫B肝细胞癌的临床意义”的回复
Ryu Sasaki,Shigeo Shimose,Issei Saeki et al.
Ryu Sasaki et al.
Response to Letter to the Editor Regarding 'Practical Considerations for MRI-Derived Retreatment Response Scores in Viable HCC' [0.03%]
关于“有关基于MRI衍生的治疗后肝癌评分在有活力的肝癌中实际考虑”的回信
Weilang Wang,Yuan-Cheng Wang
Weilang Wang
Assessing Treatment Heterogeneity in Predictive Models for HCC Retreatment Response [0.03%]
预测肝癌再治疗反应的模型中评估治疗方法异质性
Hao Tan,Hangyu Liu,Xiaofeng Luan et al.
Hao Tan et al.
Indole-3-Acetic Acid Attenuates Metabolic-Associated Steatohepatitis via APC to Inhibit β-Catenin/Wnt Pathway [0.03%]
吲哚-3-乙酸通过APC抑制β-catenin/wnt信号通路从而缓解代谢性 steatohepatitis
Jia Chen,Xiang-Nan Yu,Fu-Lin Nian et al.
Jia Chen et al.
Background: Metabolic dysfunction-associated steatohepatitis (MASH) with the end stage of cirrhosis and hepatocyte carcinoma is becoming the major cause of liver transplantation and liver-related death. Few drugs are effe...
MTARC1 Inactivation Remodels Lipid Droplets to Protect Against Metabolic Fatty Liver Disease [0.03%]
MTARC1失活重塑脂滴以预防代谢性脂肪肝病
Meng Tie,Liwei Hu,Yunzhi Yang et al.
Meng Tie et al.
Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global health burden with limited treatment options. Human genetic studies have identified mitochondrial amidoxime-reducing compon...
Further Considerations on the MyWayUp Digital Intervention for Alcohol Use Disorder in Alcohol-Related Liver Disease [0.03%]
关于MyWayUp数字干预在酒精性肝病患者中治疗酒依赖的进一步思考
Yuqi Liu,Jinyong Tian
Yuqi Liu
Patatin-Like Phospholipase Domain Containing 3 I148M Variant Affects Hepatocellular Carcinoma Recurrence After Liver Resection [0.03%]
肝切除术后patatin样磷脂酶结构域蛋白3 I148M基因多态性影响肝癌复发的作用研究
Yuki Nakayama,Kazuki Takeishi,Shinji Itoh et al.
Yuki Nakayama et al.
Background: Patatin-like phospholipase domain 3 (PNPLA3) I148M (rs738409 C>G) variant has been reported as a risk factor for metabolic dysfunction-associated steatotic liver disease/steatohepatitis and contributes to hepa...
Beyond Genetic Enhancement: The Enhanced Steatosis Index Demands Risk-Stratified Thresholds and Subgroup-Specific Solutions [0.03%]
遗传增强之外：改良型脂肪变指数要求风险分层阈值和亚组特异性解决方案
Jiajing Zhao,Liping Liu
Jiajing Zhao